Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Бүрэн тодорхойлолт

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Формат:	Artigo
Хэл сонгох:	англи
Хэвлэсэн:	2011
Онлайн хандалт:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Predicting the outcome of ankylosing spondylitis therapy
-н: Vastesaeger, Nathan, зэрэг
Хэвлэсэн: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
-н: Bert Vander Cruyssen, зэрэг
Хэвлэсэн: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
-н: van der Heijde, Désirée, зэрэг
Хэвлэсэн: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
-н: Désirée van der Heijde, зэрэг
Хэвлэсэн: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
-н: Braun, Jürgen, зэрэг
Хэвлэсэн: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
-н: Jürgen Braun, зэрэг
Хэвлэсэн: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
-н: Wagner, Carrie, зэрэг
Хэвлэсэн: (2011)

Ankylosing spondylitis: an overview
-н: Joachim Sieper, зэрэг
Хэвлэсэн: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
-н: Deodhar, Atul, зэрэг
Хэвлэсэн: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
-н: Atul Deodhar, зэрэг
Хэвлэсэн: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
-н: Braun, J, зэрэг
Хэвлэсэн: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
-н: Désirée van der Heijde, зэрэг
Хэвлэсэн: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
-н: Dominique Baeten, зэрэг
Хэвлэсэн: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
-н: Jürgen Braun, зэрэг
Хэвлэсэн: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
-н: Jürgen Braun, зэрэг
Хэвлэсэн: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
-н: Jürgen Braun, зэрэг
Хэвлэсэн: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
-н: Inman, Robert D., зэрэг
Хэвлэсэн: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
-н: Xenofon Baraliakos, зэрэг
Хэвлэсэн: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
-н: Braun, Jürgen, зэрэг
Хэвлэсэн: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
-н: Jürgen Braun, зэрэг
Хэвлэсэн: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
-н: Cruyssen, Bert Vander, зэрэг
Хэвлэсэн: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
-н: Bert Vander Cruyssen, зэрэг
Хэвлэсэн: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
-н: Annelies Boonen, зэрэг
Хэвлэсэн: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
-н: Braun, Jürgen, зэрэг
Хэвлэсэн: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
-н: Sambrook, Philip N., зэрэг
Хэвлэсэн: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
-н: Philip N. Sambrook, зэрэг
Хэвлэсэн: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
-н: Braun, Jürgen, зэрэг
Хэвлэсэн: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
-н: Zochling, J, зэрэг
Хэвлэсэн: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
-н: Désirée van der Heijde, зэрэг
Хэвлэсэн: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
-н: Ben A. C. Dijkmans, зэрэг
Хэвлэсэн: (2009)

Ankylosing spondylitis: an overview
-н: Sieper, J, зэрэг
Хэвлэсэн: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
-н: Sudha Visvanathan, зэрэг
Хэвлэсэн: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
-н: Braun, J, зэрэг
Хэвлэсэн: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
-н: Jürgen Braun, зэрэг
Хэвлэсэн: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
-н: Davis, J C, зэрэг
Хэвлэсэн: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
-н: Désirée van der Heijde, зэрэг
Хэвлэсэн: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
-н: Braun, J, зэрэг
Хэвлэсэн: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
-н: Désirée van der Heijde, зэрэг
Хэвлэсэн: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
-н: Vosse, D, зэрэг
Хэвлэсэн: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
-н: Jürgen Braun, зэрэг
Хэвлэсэн: (2016)